AstraZeneca’s Revised US Trial Result Shows 76% Efficacy

AstraZeneca releases revised trial results after the accuracy of the initial results were questioned.

Publishing revised results of the US Phases 3 trials, AstraZeneca says its COVID vaccine has 76% efficacy in preventing symptomatic illness, reported Reuters.

This new result – which is slightly lower than the earlier published 79% – comes after health experts in the US publicly called out the initial trial results.